Avidity Biosciences, Inc. Stock Price, News & Analysis

Avidity Biosciences (Nasdaq: RNA), a developer of Antibody Oligonucleotide Conjugates (AOCs™), has announced its participation in three major upcoming investor conferences in March 2025:

• TD Cowen 45th Annual Health Care Conference - March 4, 2025, at 3:10 p.m. ET
• Leerink Partners Global Healthcare Conference - March 11, 2025, at 1:00 p.m. ET
• Barclays 27th Annual Global Healthcare Conference - March 12, 2025, at 11:30 a.m. ET

The company will participate in fireside chats at each event. Live webcasts and archived replays will be available through Avidity's investor relations website.

Avidity Biosciences (RNA) has granted equity awards to 22 new non-executive employees under its 2022 Employment Inducement Incentive Award Plan. The awards, approved on February 20, 2025, include non-qualified stock options to purchase 107,000 shares and 53,500 restricted stock units (RSUs).

The stock options have an exercise price of $32.53 per share, matching Avidity's closing price on Nasdaq on February 20, 2025. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months. The RSUs will vest in four equal annual installments. Both awards require continued employment with Avidity and were granted as employment inducements under Nasdaq Rule 5635(c)(4).

Avidity Biosciences (RNA) has granted equity awards to one new non-executive employee under its 2022 Employment Inducement Incentive Award Plan. The grants include a non-qualified stock option to purchase 10,500 shares of common stock at $28.92 per share and 5,250 restricted stock units (RSUs).

The stock options will vest over four years, with 25% vesting after one year from December 20, 2024, and the remaining vesting monthly over 36 months. The RSUs will vest in four equal annual installments. These awards were granted as employment inducements in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to continued employment with Avidity.

Avidity Biosciences (Nasdaq: RNA) has announced inducement grants to its new Chief Technical Officer, Charles Calderaro III. The grants include a non-qualified stock option to purchase 80,000 shares of common stock and 40,000 restricted stock units (RSUs) under the company's 2022 Employment Inducement Incentive Award Plan.

The stock option has an exercise price of $31.42 per share, matching Avidity's closing price on Nasdaq on January 6, 2025. The stock options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months. The RSUs will vest in four equal annual installments. Both grants are subject to Mr. Calderaro's continued employment with Avidity.

Avidity Biosciences (RNA) announced significant plans for 2025, including its first Biologics License Application (BLA) submission for del-zota in treating Duchenne muscular dystrophy. The company confirmed an accelerated approval path and plans for multiple product launches in DMD44, DM1, and FSHD rare muscle diseases.

The company is expanding its leadership team with Eric Mosbrooker as Chief Commercial Officer, Charles Calderaro III as Chief Technical Officer, and Kat Lange as Chief Business Officer to support global commercialization efforts.

Key 2025 milestones include: BLA submission for del-zota by year-end, completion of enrollment in del-desiran HARBOR Phase 3 trial and del-brax biomarker cohort by mid-2025, and initiation of a global pivotal trial for del-brax. Marketing applications for del-desiran are planned for 2026 in the U.S. and European Union.

Avidity Biosciences (RNA) has granted equity awards to 37 new non-executive employees under its 2022 Employment Inducement Incentive Award Plan. The grants include 720,400 non-qualified stock options with an exercise price of $31.82 per share and 276,200 restricted stock units (RSUs).

The stock options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months. The RSUs will vest in four equal annual installments. These awards were granted as employment inducements in accordance with Nasdaq Listing Rule 5635(c)(4).

Avidity Biosciences (Nasdaq: RNA), a developer of Antibody Oligonucleotide Conjugates (AOCs™), has announced its participation in the upcoming 7th Annual Evercore ISI HealthCONx Conference. The presentation is scheduled for December 3 at 9:30 a.m. PT / 12:30 p.m. ET. Interested parties can access a live webcast and replay of the event through the company's investor relations website under the 'Events and Presentations' section.

Avidity Biosciences (RNA) has granted equity awards to 12 new non-executive employees under its 2022 Employment Inducement Incentive Award Plan. The grants include non-qualified stock options to purchase 117,000 shares and 58,500 restricted stock units (RSUs). The stock options have an exercise price of $43.65 per share, equal to the closing price on November 20, 2024. The options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. RSUs will vest in four equal annual installments, subject to continued employment.

Avidity Biosciences (Nasdaq: RNA) has expanded into precision cardiology with two new development candidates: AOC 1086 for PLN Cardiomyopathy and AOC 1072 for PRKAG2 Syndrome. Preclinical studies showed approximately 80% reduction in cardiac PLN mRNA and PRKAG2 mRNA through direct siRNA delivery to the heart. The company also revealed next-generation technology innovations demonstrating up to 30-fold increase in siRNA delivery to skeletal muscle and three-month sustained target inhibition in preclinical studies. Both candidates were well-tolerated with no effect on cardiac safety parameters. AOC 1072 data will be presented at the AHA Scientific Sessions 2024.